MeSH D006402 - hematologic diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006402:Â
Hematologic diseases
D001778:Blood coagulation disorders
0 Companies
0 Drugs
Success rate
D001791:Blood platelet disorders
0 Companies
0 Drugs
Success rate
D001855:Bone marrow diseases
D004899:Fetal erythroblastosis
0 Companies
0 Drugs
Success rate
D006453:Hemoglobinopathies
0 Companies
0 Drugs
Success rate
D007960:Leukocyte disorders
0 Companies
0 Drugs
Success rate
D008708:Methemoglobinemia
D011086:Polycythemia
0 Companies
0 Drugs
Success rate
D011250:Hematologic pregnancy complications
D011289:Preleukemia
0 Companies
0 Drugs
Success rate
D013436:Sulfhemoglobinemia
0 Companies
0 Drugs
Success rate
D019337:Hematologic neoplasms
D019851:Thrombophilia
0 Companies
0 Drugs
Success rate
D065227:Transfusion reaction
0 Companies
0 Drugs
Success rate
D000095542:Cytopenia
0 Companies
0 Drugs
Success rate
D000740:Anemia
D007938:Leukemia
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Methylprednisolone | Methylprednisolone |  | 2006-10-27 |  |  |
| Novast Laboratories | Methylprednisolone | Methylprednisolone |  | 2019-01-09 |  |  |
| Sandoz | Methylprednisolone | Methylprednisolone |  | 1997-10-31 |  |  |
| Organon | Methylprednisolone | Methylprednisolone |  | 1982-06-25 |  |  |
| Pfizer | Methylprednisolone | Depo-medrol |  | 1982-01-01 |  |  |
| Methylprednisolone | Medrol |  | 1982-01-01 | $339 M | Y2023 | |
| Zydus Therapeutics | Methylprednisolone | Methylprednisolone |  | 2018-04-23 |  |  |
| Hospira | Methylprednisolone | A-methapred |  | 2005-12-20 |  |  |
| Amneal Pharmaceuticals | Methylprednisolone | Methylprednisolone |  | 2021-09-21 |  |  |
| Bristol Myers Squibb | Idecabtagene vicleucel | Abecma |  | 2021-08-18 | $419 M | Q3/24-Q2/25 |
| Par Pharmaceutical | Methylprednisolone | Methylprednisolone |  | 1988-04-25 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
81%29/36
Phase 2
16%10/63
Phase 3
12%2/17
Approved: 2Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use